Your browser doesn't support javascript.
loading
Short- and long-term survival in patients over 90 years old undergoing pacemaker implantation.
Zecchin, Massimo; Trevisan, Boris; Baggio, Chiara; Bessi, Riccardo; Saitta, Monica; Salvatore, Luca; Cappelletto, Chiara; Gregorio, Caterina; Bianco, Elisabetta; Longaro, Fulvia; Carriere, Cosimo; Zorzin-Fantasia, Anna; Piccinin, Francesca; Dal Monte, Giovanni; Sinagra, Gianfranco.
Afiliação
  • Zecchin M; Cardiovascular Department, Azienda Sanitaria Universitaria Integrata Giuliano Isontina, University of Trieste, Trieste, Italy.
J Cardiovasc Med (Hagerstown) ; 24(9): 625-630, 2023 09 01.
Article em En | MEDLINE | ID: mdl-37605954
ABSTRACT

AIMS:

In Italy, 12-month survival in the general population between 90 and 94 years old is 26%. In very old patients, the benefit of pacemaker implantation in terms of quality and duration of life is unclear. The aim of our study was to analyse clinical characteristics, outcome and factors associated with survival in patients at least 90 years old at the time of the first pacemaker implant.

METHODS:

Clinical parameters, device characteristics, survival and predictors of outcome in patients at least 90 years old treated with a pacemaker in our centre in 2019-2020 were evaluated.

RESULTS:

Among the 554 patients undergoing pacemaker implantation in our centre during the study interval, 69 (12%) were at least 90 years old; a complete/advanced atrioventricular block was present in 65%. A cardiological comorbidity (excluding atrial fibrillation) was present in 22 patients (32%). Oncological, pulmonary and neurological comorbidities were present in 12 (17%), 19 (28%) and 32 (46%), respectively. Renal impairment was present in 25 patients (36%). After pacemaker implantation, a pneumothorax developed in two patients and lead dislodgment in one. During follow-up (median 17 months, interquartile range 13-24), 32 patients died (46%), with a 12-month mortality probability of 24.6%. At multivariate analysis, the presence of oncological (hazard ratio (HR) 5.31; P < 0.001) and neurological (HR 6.44; P < 0.001) comorbidities was associated with mortality. Truncating the outcome at 6 months, renal impairment (HR 8.01; P = 0.003), anticoagulant therapy (HR 8.14; P = 0.003), oncological comorbidities (HR 14.1; P < 0.001) and left ventricular function (5% increase of left ventricular ejection fraction HR 0.66; P < 0.001) were significantly associated with outcome.

CONCLUSION:

At our centre, patients at least 90 years old underwent pacemaker implantation mainly for advanced atrioventricular block. One-year survival was excellent, even better than expected in the general population.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Fibrilação Atrial / Cardiologia / Bloqueio Atrioventricular Tipo de estudo: Prognostic_studies Limite: Aged80 / Humans País/Região como assunto: Europa Idioma: En Revista: J Cardiovasc Med (Hagerstown) Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Fibrilação Atrial / Cardiologia / Bloqueio Atrioventricular Tipo de estudo: Prognostic_studies Limite: Aged80 / Humans País/Região como assunto: Europa Idioma: En Revista: J Cardiovasc Med (Hagerstown) Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália